organ ebit headwind remain
net dbt
perform challeng take time work
wba despit in-lin ep ep guidanc consensu
highlight pressur busi current face combin
slower script/front end growth gross margin pressur continu weigh
core even off-set sg manag structur well
one-tim benefit quarter meanwhil trend driven gross
margin lower reimburs pressur pbm declin gener price fall
brand inflat remain play leav limit opportun drive broad-bas
gross profit dollar growth organ basi compani recent announc
partnership across healthcar retail could help reposit busi
labcorp particular sizabl opportun still see potenti financi
benefit take longer materi result maintain under-perform
although increas price object higher non-
oper ep util target price-to-earnings multipl
increas ep ep
almost entir driven below-the-lin item slightli better sg
manag off-set slightli lower gross margin new po repres
ep discount histor rang reflect recent ebit growth
challeng well emerg competit threat across market
upcom event catalyst
key focu investor gain increment comfort around scope
financi contribut recent struck partnership particularli labcorp
separ addit prefer part relationship file buy could act
catalyst share anoth catalyst includ gener updat market growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
walgreen follow complet rite
aid store acquisit largest global
pharmaci nearli store us
alon compani also oper intern
pharmaci busi primarili compos
boot pharmaci unit kingdom
allianc healthcar intern wholesal
distributor pharmaceut medic
product europ walgreen headquart
under-perform rate predic
market headwind competit dynam
exacerb concern around pend
amazon entri market core profit
dollar growth slow think limit visibl
creat challeng near-term stock
perform view range-bound
note earn call
note prepar remark
compar store front store sale
reimburs pressur gener neg impact
compar sale growth partial off-set brand inflat
sg decreas percentag point percentag sale
sale declin constant currenc basi
lower sale driven lower rx volum declin uk pharmaci
oper incom constant currenc basi
sale increas strong growth emerg market
oper incom constant currenc basi
posit integr good rx retent
aim complet store optim end
anticip store optim benefit ahead
reduc work capit year
adjust ep constant currenc
tax rate depend level discret
item year
headwind store invest
close stefano
differenti evolv retail offer
note
guidanc investor think ep growth compani think
organ growth
growth come share repurchas
low end ex-buyback high end
probabl similar trend
expect distinct improv gross margin compani move
synergi next year ramp
expect store front end sale improv promot sale
wind
pharmaci side cycl pharmaci network
amazon minimum wage increas impact compani abil
announc primarili go store
remain confid local level
amazon primarili recruit warehous differ
retail shop
ep growth ex share repurchas seem tax interest off-set one
anoth commentari sg control versu core gross profit growth
benefit gener purchas wind bit
believ compani better sg cost control
gross margin similar latter part see
improv trend last quarter
fep contract specialti creat messi margin profil fep
take fep much chang gross margin
lap fep margin look flatter
labcorp partnership think expans relat
conveni platform patient
econom good enough
baseline/organ growth exclud acquisit
believ aggress sg procur
went prefer non-pref aetna grown
despit
think core busi volum strong
dont underestim benefit invest store system
author gener strategi gilead impact pharmaci
opportun author gener
compani remain competit
grew aoi last year lap tough quarter
quarter stronger headlin suggest
tax headwind tailwind
flat benefit
tax reform benefit percentag point off-set
neg compon tax
open ad valu sharehold
price object base ep multipl
five-year averag absolut basi around discount five-year
averag reflect view walgreen core retail pharmaci busi long-
term structur pressur must diversifi stabl busi line improv
upsid risk better expect gener save addit volum
econdisc/rit aid new partnership healthcar support long-term growth
faster expect growth prime relationship downsid risk
po greater expect prescript attrit part relationship
integr risk risk amazon anoth disrupt forc
enter suppli chain market lack avail attract capit deploy
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
